Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ACAD logo ACAD
Upturn stock ratingUpturn stock rating
ACAD logo

ACADIA Pharmaceuticals Inc (ACAD)

Upturn stock ratingUpturn stock rating
$22.12
Last Close (24-hour delay)
Profit since last BUY28.9%
upturn advisory
Regular Buy
BUY since 31 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/27/2025: ACAD (3-star) is a REGULAR-BUY. BUY since 31 days. Profits (28.90%). Updated daily EoD!

Upturn Star Rating

ratingratingratingratingrating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Number of Analysts

rating

20 Analysts rated it

These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.

Year Target Price $26.68

Year Target Price $26.68

Analyst’s Price TargetsFor last 52 week
$26.68Target price
Low$13.4
Current$22.12
high$25.23

Analysis of Past Performance

Type Stock
Historic Profit 33.57%
Avg. Invested days 44
Today’s Advisory Regular Buy
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/27/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 3.70B USD
Price to earnings Ratio 16.15
1Y Target Price 28.47
Price to earnings Ratio 16.15
1Y Target Price 28.47
Volume (30-day avg) -
Beta 0.65
52 Weeks Range 13.40 - 25.23
Updated Date 06/29/2025
52 Weeks Range 13.40 - 25.23
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) 1.37

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin 22.97%
Operating Margin (TTM) 7.9%

Management Effectiveness

Return on Assets (TTM) 5.56%
Return on Equity (TTM) 37.24%

Valuation

Trailing PE 16.15
Forward PE 50.25
Enterprise Value 3076473144
Price to Sales(TTM) 3.72
Enterprise Value 3076473144
Price to Sales(TTM) 3.72
Enterprise Value to Revenue 3.09
Enterprise Value to EBITDA 30.26
Shares Outstanding 167362000
Shares Floating 114821945
Shares Outstanding 167362000
Shares Floating 114821945
Percent Insiders 0.68
Percent Institutions 105.59

Analyst Ratings

Rating 3.95
Target Price 26.68
Buy 6
Strong Buy 7
Buy 6
Strong Buy 7
Hold 6
Sell 1
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

ACADIA Pharmaceuticals Inc

stock logo

Company Overview

overview logo History and Background

ACADIA Pharmaceuticals Inc. was founded in 1993. Initially focused on drug discovery using innovative technologies, it transitioned to developing and commercializing treatments for central nervous system disorders. A key milestone was the FDA approval of Nuplazid (pimavanserin) in 2016 for Parkinson's disease psychosis.

business area logo Core Business Areas

  • Neurology: Focuses on developing and commercializing therapies for neurological disorders. Their main product is NUPLAZID for Parkinson's disease psychosis.
  • Psychiatry: Focuses on developing and commercializing therapies for psychiatric disorders. They are exploring new indications for NUPLAZID and other potential products.

leadership logo Leadership and Structure

The company is led by Steve Davis (CEO). The organizational structure consists of research and development, commercial operations, and corporate functions.

Top Products and Market Share

overview logo Key Offerings

  • NUPLAZID (pimavanserin): NUPLAZID is an atypical antipsychotic approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). While specific market share data is difficult to obtain precisely, it is the dominant treatment for PDP. Revenue from NUPLAZID is the primary revenue driver for ACADIA. Competitors include off-label use of typical and atypical antipsychotics, which have significant safety concerns in the elderly Parkinson's population.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry is highly competitive and regulated. The CNS market is characterized by unmet needs and opportunities for innovative therapies.

Positioning

ACADIA is a specialty pharmaceutical company focused on CNS disorders. Its competitive advantage lies in its approved therapy, NUPLAZID, and its pipeline of potential treatments for underserved populations.

Total Addressable Market (TAM)

The TAM for treatments of psychosis and other CNS disorders is substantial, estimated to be in the billions of dollars. ACADIA is positioned to capture a significant portion of this TAM, particularly with expansion into new indications.

Upturn SWOT Analysis

Strengths

  • FDA-approved product (NUPLAZID)
  • Strong focus on CNS disorders
  • Expanding pipeline of potential therapies
  • Specialized sales force targeting neurologists and psychiatrists

Weaknesses

  • Reliance on a single product (NUPLAZID) for revenue
  • Potential for generic competition
  • Risk associated with clinical trials
  • Negative publicity surrounding historical data analysis

Opportunities

  • Expansion of NUPLAZID into new indications (e.g., dementia-related psychosis)
  • Acquisition or licensing of new CNS therapies
  • Partnerships with other pharmaceutical companies
  • Growing awareness of CNS disorders and unmet needs

Threats

  • Competition from other pharmaceutical companies
  • Regulatory hurdles and delays
  • Pricing pressures and reimbursement challenges
  • Adverse events or safety concerns related to NUPLAZID

Competitors and Market Share

competitor logo Key Competitors

  • JAZZ
  • TEVA
  • MYL

Competitive Landscape

ACADIA has a strong position in Parkinson's disease psychosis with NUPLAZID. However, it faces competition from companies with broader CNS portfolios and generic manufacturers.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been primarily driven by the sales growth of NUPLAZID.

Future Projections: Future growth is dependent on expansion of NUPLAZID into new indications and the success of pipeline candidates. Analyst estimates vary depending on these factors.

Recent Initiatives: Recent initiatives include clinical trials for new indications of NUPLAZID and development of other CNS therapies.

Summary

ACADIA Pharmaceuticals is primarily fueled by NUPLAZID sales, offering a unique treatment for Parkinson's disease psychosis. While the company shows revenue growth, profitability remains a concern. Expansion into new indications and successful pipeline development are crucial for future success. Competition and regulatory risks need to be carefully managed.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Filings (SEC)
  • Analyst Reports
  • Company Website
  • Market Research Reports

Disclaimers:

The information provided is for informational purposes only and should not be considered investment advice. Market share data is based on estimates and may vary. Financial data is subject to change. The AI-based rating is generated using available information and should be interpreted with caution.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About ACADIA Pharmaceuticals Inc

Exchange NASDAQ
Headquaters San Diego, CA, United States
IPO Launch date 2004-05-27
CEO & Director Ms. Catherine E. Owen Adams
Sector Healthcare
Industry Biotechnology
Full time employees 653
Full time employees 653

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to treat the negative symptoms of schizophrenia; ACP-101, which completed phase III clinical trial for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 that completed phase II clinical trial for the treatment of Alzheimer's disease psychosis and Lewy Body Dementia with psychosis; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; ACP-211 that is in phase I clinical trial for the treatment of treatment-resistant depression; ACP-2591 that is in Phase I development for Rett syndrome and Fragile X syndrome; and ACP-271, a GPR88 agonist used in evaluation of neurology and is in the IND-enabling stage. The company has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.